Article
Clinical Neurology
Laura Melgarejo, Edoardo Caronna, Joana Rosell-Mirmi, Iker Elosua-Bayes, Alicia Alpuente, Marta Torres-Ferrus, Victor J. Gallardo, Patricia Pozo-Rosich
Summary: This study aimed to investigate the link between COVID-19 and COVID-19 vaccination with migraine worsening. The findings suggest that the infection and vaccination have a negligible role in migraine worsening and there may be a presence of a nocebo effect.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Rehab Magdy, Alaa Elmazny, Shaimaa H. Soliman, Eman H. Elsebaie, Sara H. Ali, Ali M. Abdel Fattah, Mahmoud Hassan, Ahmed Yassien, Noha A. Mahfouz, Radwa M. Elsayed, Wael Fathy, Hoda M. Abdel-Hamid, Jehan Mohamed, Mona Hussein
Summary: This study investigated the post-COVID-19 neuropsychiatric symptoms in migraine patients compared to a non-migraine control group. The findings suggest that migraine patients may be more vulnerable to experiencing symptoms such as fatigue, anosmia/hyposmia, anxiety, and headache after recovering from COVID-19. This highlights the importance of closely monitoring and caring for migraine patients during their recovery.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Jasem Youssef Al-Hashel, Fathi Abokalawa, Maram Alenzi, Raed Alroughani, Samar Farouk Ahmed
Summary: The study findings indicate that primary headaches worsen after COVID-19 infections, but most patients experience resolution of de novo headaches within one month post-infection. Headaches related to COVID-19 are severe and predominantly present as migraines, with young male patients exhibiting more severe symptoms.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Medicine, General & Internal
Marcello Silvestro, Alessandro Tessitore, Ilaria Orologio, Pasquale Sozio, Giuseppe Napolitano, Mattia Siciliano, Gioacchino Tedeschi, Antonio Russo
Summary: A study shows that migraine patients may experience more severe, longer-lasting, and harder to treat headaches after receiving the COVID-19 vaccine, possibly due to the production of inflammatory mediators.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Angelo Torrente, Paolo Alonge, Vincenzo Di Stefano, Roberta Baschi, Raffaele Ornello, Edvige Correnti, Antonino Lupica, Cecilia Camarda, Gabriella Farinella, Vincenzo Raieli, Simona Sacco, Roberto Monastero, Filippo Brighina
Summary: This study describes the characteristics of patients who develop new-onset headache following SARS-CoV-2 infection. The results show that the timing and characteristics of headache vary among patients, and the response to treatment also varies.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Faraidoon Haghdoost, Cheryl Carcel, Deepak Chandrasekhar, Anthony Rodgers, Candice Delcourt
Summary: The study found that there was an increase in migraine frequency in 2020 compared to 2019, with stress, lack of sleep, neck pain, and anxiety being the most common triggers. The survey indicated that while the use of telehealth consultations increased, migraine patients still preferred face-to-face consultations.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Heather Angus-Leppan, Angelica E. Guiloff, Karen Bensons, Roberto J. Guiloff
Summary: The treatment gap for migraine has widened during the COVID-19 pandemic as attention has shifted to the international emergency. Telemedicine has been effective for migraine follow-up, with ongoing evaluation needed. It is important to avoid drug interactions and close contact procedures in acute COVID-19 cases, while also acknowledging the potential secondary effects of the virus on those with migraine.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Laura Rapisarda, Michele Trimboli, Francesco Fortunato, Antonio De Martino, Oreste Marsico, Giulio Demonte, Antonio Augimeri, Angelo Labate, Antonio Gambardella
Summary: The study examined headache variations related to intensive facemask usage among healthcare professionals in Italy, with some previously headache-free individuals developing de novo headaches and existing primary headache disorders exacerbating, especially for those with migraine.
NEUROLOGICAL SCIENCES
(2021)
Article
Medicine, Research & Experimental
Jordi Gonzalez-Menacho, Monica Villas-Roca, Helena Castane, Jorge Joven, Jordi Camps, Simona Iftimie
Summary: This article presents 8 clinical cases of patients with chronic headache, in which the symptoms were completely or partially resolved after receiving COVID-19 vaccination. The administration of vaccines may inhibit the synthesis of pro-inflammatory cytokines, leading to an improvement or disappearance of symptoms in these patients.
MEDICAL HYPOTHESES
(2022)
Review
Clinical Neurology
Mansoureh Togha, Seyedeh Melika Hashemi, Nooshin Yamani, Fahimeh Martami, Zhale Salami
Summary: Since the discovery of SARS-CoV-2 in December 2019, there have been numerous studies on COVID-19 and its neurological impact. Headaches have been reported as a common neurological manifestation of COVID-19, but the exact mechanism and features of these headaches are still unclear. This review study outlines the types of headaches reported in previous studies and their possible pathogenic mechanisms. It also discusses the persistent headache after recovery and the impact of COVID-19 vaccination on headaches.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Alvaro Planchuelo-Gomez, David Garcia-Azorin, Angel L. Guerrero, Margarita Rodriguez, Santiago Aja-Fernandez, Rodrigo de Luis-Garcia
Summary: Patients with persistent headache after COVID-19 resolution show diverse changes in brain structure, including both gray matter and white matter alterations. Compared to individuals without headache, these patients have lower cortical gray matter volume and thickness, accompanied by impaired white matter fiber bundles. Compared to migraine patients, those with persistent headache after COVID-19 recovery exhibit higher cortical volume and thickness in certain brain regions, as well as lower subcortical volume. The study suggests that persistent headache after COVID-19 resolution could be considered an intermediate state between normality and migraine.
JOURNAL OF NEUROLOGY
(2023)
Article
Medicine, General & Internal
Jong-Ho Kim, Yeonkyeong Lee, Young-Suk Kwon, Jong-Hee Sohn
Summary: Migraine and non-migraine headaches (nMH) are associated with increased risks of gastrointestinal (GI) and respiratory disorders, including asthma, bronchitis, and gastroesophageal reflux disorder. This study investigated the relationship between pulmonary microbes and brain disorders, suggesting that the lung-brain axis is involved in this association. After analyzing clinical data from over 11 years, it was found that patients with migraine had significantly higher odds ratios for various GI disorders compared to controls, while patients with nMH had higher odds ratios for asthma and bronchitis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Cesar Fernandez-de-las-Penas, Marcos Navarro-Santana, Victor Gomez-Mayordomo, Maria L. Cuadrado, David Garcia-Azorin, Lars Arendt-Nielsen, Gustavo Plaza-Manzano
Summary: This study analyzed the prevalence of post-COVID headache in COVID-19 survivors, finding that the prevalence of headache was around 47.1% at onset or hospital admission, 10.2% at 30 days, 16.5% at 60 days, 10.6% at 90 days, and 8.4% at >=180 days. Headache as a symptom at the acute phase was more prevalent in non-hospitalized patients compared to hospitalized patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Dina Karvounides, Maya Marzouk, Alexandra C. Ross, Juliana H. VanderPluym, Christina Pettet, Ali Ladak, Jason Ziplow, Carlyn Patterson Gentile, Scott Turner, Marissa Anto, Rebecca Barmherzig, Madeline Chadehumbe, Jocelyn Kalkbrenner, Carrie P. Malavolta, Michelle A. Clementi, Trevor Gerson, Christina L. Szperka
Summary: The study aims to provide clinicians with specific recommendations for youth with headache disorders impacted by the COVID-19 pandemic. The return to school in 2020 poses challenges for caregivers and youth with migraine, but there are recommendations available to help minimize negative effects on their physical, emotional, and social health.
Article
Clinical Neurology
Bianca Raffaelli, Jasper Mecklenburg, Simon Scholler, Lucas Hendrik Overeem, Ana Sofia Oliveira Goncalves, Uwe Reuter, Lars Neeb
Summary: Lockdown measures during the COVID-19 pandemic in Germany did not significantly impact primary headache frequency and intensity over a 3-month period, although lifestyle factors such as stress levels, sleep duration, and activity levels showed some changes.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
F. Ly-Yang, V. Gomez-Calleja, P. Perez-Garcia, N. Gonzalez-Gomez, J. Porta-Etessam, E. Santos-Bueso
Summary: This article presents 30 clinical cases of photophobia and reviews the literature in order to establish diagnostic criteria for this condition. The results suggest that the underlying causes of photophobia may involve the intrinsically photosensitive retinal ganglion cells as well as neurochemical factors like calcitonin-related peptide and the pituitary activating peptide cyclase. The treatment for photophobia could potentially involve the use of monoclonal antibodies targeting calcitonin-related peptide and/or pituitary activating peptide cyclase.
Article
Clinical Neurology
Benedict D. Michael, Dean Walton, Erica Westenberg, David Garcia-Azorin, Bhagteshwar Singh, Arina A. Tamborska, M. Netravathi, Mashina Chomba, Greta K. Wood, Ava Easton, Omar K. Siddiqi, Thomas A. Jackson, Thomas A. Pollak, Timothy R. Nicholson, Shalini Nair, Gerome Breen, Kameshwar Prasad, Kiran T. Thakur, Sherry H. -Y. Chou, Erich Schmutzhard, Jennifer A. Frontera, Raimund Helbok, Alessandro Padovani, David K. Menon, Tom Solomon, Andrea S. Winkler
Summary: Encephalopathy is a common and challenging condition among hospitalized COVID-19 patients, which can have a negative impact on prognosis. This review provides practical guidance on the management of COVID-19 encephalopathy through consensus agreement of the Global COVID-19 Neuro Research Coalition, covering definition, epidemiology, pathophysiology, clinical assessment, investigation, and both acute and long-term management.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
(2023)
Article
Clinical Neurology
Alvaro Planchuelo-Gomez, David Garcia-Azorin, Angel L. Guerrero, Margarita Rodriguez, Santiago Aja-Fernandez, Rodrigo de Luis-Garcia
Summary: Patients with persistent headache after COVID-19 resolution show diverse changes in brain structure, including both gray matter and white matter alterations. Compared to individuals without headache, these patients have lower cortical gray matter volume and thickness, accompanied by impaired white matter fiber bundles. Compared to migraine patients, those with persistent headache after COVID-19 recovery exhibit higher cortical volume and thickness in certain brain regions, as well as lower subcortical volume. The study suggests that persistent headache after COVID-19 resolution could be considered an intermediate state between normality and migraine.
JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Edoardo Caronna, Thomas C. van den Hoek, Hayrunnisa Bolay, David Garcia-Azorin, Ana Beatriz Gago-Veiga, Massimiliano Valeriani, Tsubasa Takizawa, Karl Messlinger, Robert E. Shapiro, Peter J. Goadsby, Messoud Ashina, Cristina Tassorelli, Hans-Christoph Diener, Gisela M. Terwindt, Patricia Pozo-Rosich
Summary: This article summarizes the knowledge on the epidemiology, pathophysiology, and management of secondary headache associated with SARS-CoV-2 infection and vaccination, as well as their impact on primary headache disorders. It was found that headache is a common symptom of both acute and post-acute phase of SARS-CoV-2 infection, and specific effective therapeutic options are currently lacking. Headache attributed to SARS-CoV-2 vaccinations is also common, but its pathophysiology remains unclear. People with primary headache disorders are more likely to experience headache during the acute phase of COVID-19 and after vaccination.
Editorial Material
Clinical Neurology
Edoardo Caronna, Patricia Pozo-Rosich
Review
Clinical Neurology
Faraidoon Haghdoost, Francesca Puledda, David Garcia-Azorin, Eva-Maria Huessler, Roberta Messina, Patricia Pozo-Rosich
Summary: This study evaluated the efficacy of novel treatments targeting the calcitonin gene-related peptide pathway for the prevention of migraine. The results showed that these medications significantly reduced monthly migraine and headache days, and had higher responder rates compared to placebo.
Article
Clinical Neurology
Marta Torres-Ferrus, Victor J. J. Gallardo, Alicia Alpuente, Edoardo Caronna, Eulalia Gine-Cipres, Patricia Pozo-Rosich
Summary: This study examines the patterns of response to anti-CGRP MAbs in migraine patients during the first 6 months of treatment and its association with baseline clinical characteristics. The initial response to anti-CGRP MAbs varies among patients, and persistence of anxiety and depression may affect treatment response at 6 months.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Cesar Fernandez-de-Las-Penas, Maria L. Cuadrado, Victor Gomez-Mayordomo, David Garcia-Azorin, Lars Arendt-Nielsen
Summary: This article analyzes the differences in the prevalence of headache as an onset symptom and in post-COVID headache among the different SARS-CoV-2 variants (historical strain, Alpha, Delta, and Omicron) and discusses the different pathophysiological mechanisms by which SARS-CoV-2 infection may cause headache.
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2023)
Article
Clinical Neurology
J. Porta-Etessam, S. Santos-Lasaosa, J. Rodriguez-Vico, M. Nunez, A. Ciudad, S. Diaz-Cerezo, M. Comellas, F. J. Perez-Sadaba, L. Lizan, A. L. Guerrero-Peral
Summary: Shared decision-making (SDM) training for neurologists in migraine care does not significantly impact patients’ decisional conflict and patient-physician relationship. However, physicians reported greater satisfaction and confidence in communicating with patients after the training.
NEUROLOGY AND THERAPY
(2023)
Article
Clinical Neurology
Alicia Alpuente, Anna Torre-Sune, Edoardo Caronna, Eulalia Gine-Cipres, Marta Torres-Ferrus, Patricia Pozo-Rosich
Summary: This study evaluated the impact of basal accompanying symptoms on anti-CGRP monoclonal antibodies treatment response and their evolution after six months of treatment in migraine patients. The results showed that the occurrence rates of accompanying symptoms decreased more in patients with a better response. The baseline photophobia ratio was positively correlated with the response rate between three and six months.
Article
Clinical Neurology
Cristina Garcia-Iglesias, Ana Gonzalez-Celestino, Alvaro Sierra Mencia, Yesica Gonzalez Osorio, Andrea Recio Garcia, Cristina Martinez-Badillo, Ana Echavarria Iniguez, Berta Varona-Galan, David Garcia-Azorin, Angel Luis Guerrero-Peral
Summary: The long-term outcomes of nummular headache (NH) are generally positive, with a substantial number of patients experiencing inactive NH after a median follow-up period of 6.7 years. Preventive treatment is required by the majority of patients, but most of them respond well to the treatment. For patients with persistent symptoms, the frequency of headaches is lower.
Review
Clinical Neurology
Carmen Sanchez-Rodriguez, Ana Beatriz Gago-Veiga, David Garcia-Azorin, Angel Luis Guerrero-Peral, Alicia Gonzalez-Martinez
Summary: This review summarizes the latest research findings on predictors of response to anti-CGRP therapies in patients with chronic migraine. The study suggests that migraine features (such as unilateral pain and positive triptan response) and chronic features (such as daily headache or medication overuse) may be linked to elevated baseline serum anti-CGRP levels.
CURRENT PAIN AND HEADACHE REPORTS
(2023)
Article
Clinical Neurology
Laura Melgarejo, Edoardo Caronna, Joana Rosell-Mirmi, Iker Elosua-Bayes, Alicia Alpuente, Marta Torres-Ferrus, Victor J. Gallardo, Patricia Pozo-Rosich
Summary: This study aimed to investigate the link between COVID-19 and COVID-19 vaccination with migraine worsening. The findings suggest that the infection and vaccination have a negligible role in migraine worsening and there may be a presence of a nocebo effect.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, Seiya Ohtani, Narumi Watanabe, Noboru Imai, Jin Nakahara, Satoko Hori, David Garcia-Azorin, Paolo Martelletti
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Article
Anesthesiology
Alicia Gonzalez-Martinez, Ancor Sanz-Garcia, David Garcia-Azorin, Jaime Rodriguez-Vico, Alex Jaimes, Andrea Gomez Garcia, Javier Casas-Limon, Javier Diaz de Teran, Maria Sastre-Real, Javier Membrilla, German Latorre, Carlos Calle de Miguel, Sendoa Gil Luque, Cristina Trevino-Peinado, Sonia Quintas, Patricia Heredia, Ana Echavarria-Iniguez, Angel Guerrero-Peral, Alvaro Sierra, Nuria Gonzalez-Garcia, Jesus Porta-Etessam, Ana Beatriz Gago-Veiga
Summary: This study evaluated the clinical characteristics, effectiveness, and tolerability of preventive anti-CGRP mAbs in the elderly. The results showed that anti-CGRP mAbs can effectively reduce the number of headaches in elderly patients with migraine, and their safety is similar to that of younger patients. In elderly patients, the diagnosis of episodic migraine and a lower baseline number of headaches were associated with a response to anti-CGRP mAbs.